This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AVR01, AVR 01
Description: AVR-01 consists of neoplastic cells engineered to express IL-12. It is designed to be a anti-cancer immunotherapy which triggers the immune system to first detect, and then eradicate, tumor cells. The patient’s cancer cells are genetically modified to express IL-12. The modified cells are then infused back into the patient via a one-time procedure, where they activate cytotoxic CD4+ T cells which specifically target tumor cells and thus eliminate the cancer. A long-lasting anti-cancer immune response is maintained via both CD4+ and CD8+ cytotoxic T cells.
Additional information available to subscribers only: